A Potential Role for Integrin-Linked Kinase in Colorectal Cancer Growth and Progression via Regulating Senescence and
Saleh Almasabi1,2,3,4, Afsar U Ahmed1, Richard Boyd2
1Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Frontiers in Genetics
|June 24, 2021
Summary
Integrin-linked kinase (ILK) plays a role in colon inflammation and colorectal cancer (CRC) development. Targeting ILK may offer a therapeutic strategy for CRC by influencing senescence and immunity.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Integrin-linked kinase (ILK) is a key mediator in colon inflammation and colorectal cancer (CRC) development.
- ILK is overexpressed in many cancers, including CRC, and links extracellular matrix to downstream signaling.
- Inflammation, particularly inflammatory bowel disease (IBD), is a significant risk factor for CRC initiation.
Purpose of the Study:
- To review the potential role of ILK in senescence and immunity within the context of CRC.
- To explore ILK's regulation of cellular processes critical for CRC development, progression, and colon inflammation.
- To examine the potential of combining ILK inhibition with Toll-like receptor (TLR) activation for CRC immunotherapy.
Main Methods:
- Literature review focusing on ILK, senescence, immunity, and CRC.
- Analysis of ILK's function in cellular processes like senescence and the senescence-associated secretory phenotype (SASP).
- Exploration of the interplay between ILK, immune cell infiltration, and tumor growth.
Main Results:
- ILK is implicated in regulating cellular senescence, a process with dual roles in cancer.
- Senescence-associated secretory phenotype (SASP) influences immune cell infiltration, impacting CRC progression.
- ILK's role in modulating senescence and immunity in CRC requires further elucidation.
Conclusions:
- ILK represents a promising therapeutic target for CRC due to its involvement in inflammation and tumorigenesis.
- Understanding ILK's role in senescence and immunity could lead to novel treatment strategies for CRC.
- Combination therapies, such as ILK inhibition with TLR agonists, may enhance anti-tumor immune responses in CRC.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
3.1K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.1K
03:03mTOR Signaling and Cancer Progression
4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.0K
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.2K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.2K
01:15Activation of Integrins
4.2K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.2K
01:22PI3K/mTOR/AKT Signaling Pathway
4.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.3K
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.4K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.4K